Science

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong/immunooncologyindia.com

Apr 7, 2025, 11:42

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO), shared an article by A.C. Chiang, et al. on LinkedIn:

“Happy to share our recent ESMO Open paper on the safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy.

Luis Paz-Ares, Noemi Reguart, Shirish Gadgeel and others.”

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Authors: A.C. Chiang, et al.

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

American Society of Clinical Oncology ASCO cancer DeLLphi300 ESMO Open fight against cancer Global fight against cancer Herbert Loong Luis Paz-Ares Noemi Reguart OncoDaily Oncology Shirish Gadgeel Tarlatamab

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing

Vinay Prasad Rejoins FDA Days After Exit